| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/14/2003 | US6506380 Methods of preventing or treating allergies |
| 01/14/2003 | CA2194444C Immunomodulators |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002607A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002542A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002540A1 Cyclic diamine compound having five-membered cyclic group |
| 01/09/2003 | WO2003002539A1 Dibenzocycloheptene compound |
| 01/09/2003 | WO2003002538A1 Bis(2-aryl-5-pyridyl) derivative |
| 01/09/2003 | WO2003002537A1 Bis(5-aryl-2-pyridyl) derivative |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002511A1 Cycloalkenone derivative |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002135A2 Herbal composition |
| 01/09/2003 | WO2003002125A2 Combination of aminosugars and cysteine or cysteine derivatives |
| 01/09/2003 | WO2003002124A1 USE OF BIS-ACID(5-ANDROSTEN-17-ONE-3β-HYDROXYL) DIESTERS FOR MANUFACTURE PHARMACEUTICALS |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002117A2 Niaciamide and derivatives in combination with aminosugar |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002090A1 Immunopotentiator for mammary gland of dairy cows containing lactoferrin as an active ingredient |
| 01/09/2003 | WO2003002069A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003001891A2 Method and apparatus for computer modeling of an adaptive immune response |
| 01/09/2003 | WO2003001877A2 Methods for the diagnosis and treatment of cardiac tissue rejection |
| 01/09/2003 | WO2002092795A3 Intracellular bonding of costimulatory molecules |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002071062A9 Diagnosis and treatment of inflammation and hyperactive immune conditions |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002059081A3 Urea derivatives as inhibitors of ccr-3 receptor |
| 01/09/2003 | WO2002047686A8 Substituted-4-quinolones |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002026997A3 Dsp-16 dual-specificity phosphatase |
| 01/09/2003 | WO2002013855A3 Vaccines containing ribavirin and methods of use thereof |
| 01/09/2003 | WO2002009762A3 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | WO2001055333A9 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008839 Use of a dimethyldialkylammonium salt as an adjuvant for a nucleic acid vaccine |
| 01/09/2003 | US20030008835 Bioavailability of drug substance, are convenient to administer, and are stable |
| 01/09/2003 | US20030008834 Compsoitions and methods for treating epithelia and retinal tissue diseases |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008016 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 01/09/2003 | US20030007978 Quantiative analysis; genetic engineering |
| 01/09/2003 | US20030007977 Vaccine containing amino acid |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007966 Adult respiratory distress syndrome |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2452371A1 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |